LB Pharmaceuticals Inc
LBRXLB Pharmaceuticals is a late-stage biopharmaceutical company focused on developing novel benzamide therapies for neuropsychiatric disorders, including schizophrenia and mood disorders.
Earnings
Next report
Nov 5, 2026 (in 2 months)Financials
Q1 2026Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
LB Pharmaceuticals is a late-stage biopharmaceutical company focused on developing novel benzamide therapies for neuropsychiatric disorders, including schizophrenia and mood disorders. Its core value proposition centers on LB-102, a patented derivative of the antipsychotic amisulpride designed with improved blood-brain barrier permeability to enable once-daily dosing and a superior safety profile. The company aims to address significant unmet needs in the U.S. market by providing treatments that balance rapid efficacy with class-leading tolerability.
LB Pharmaceuticals is a clinical-stage developer seeking to introduce the first benzamide antipsychotic to the U.S. market, leveraging a mechanism of action with extensive established clinical use in Europe.
FAQ
- What is LB Pharmaceuticals Inc's market cap?
- LB Pharmaceuticals Inc (LBRX) has a market capitalization of $1.6B and trades on NASDAQ.
- Who are LB Pharmaceuticals Inc's competitors?
- LB Pharmaceuticals Inc's key competitors include Vanda Pharmaceuticals Inc., Alkermes, Inc., Karuna Therapeutics, and others. These companies compete in similar markets and product categories.
- Who does LB Pharmaceuticals Inc partner with?
- LB Pharmaceuticals Inc's notable partners include Sanofi S.A., AstraZeneca plc, AbbVie Inc., and others.
- Where is LB Pharmaceuticals Inc headquartered?
- LB Pharmaceuticals Inc is headquartered in United States of America. It has been publicly traded since 2025.